B-cell receptor recognizing Dermatophagoides farinae allergens (BCR-Der f)

The B-cell receptor (BCR) recognizing Dermatophagoides farinae allergens is a membrane-bound immunoglobulin complex expressed on the surface of B lymphocytes that specifically bind to proteins from the American house dust mite. This receptor is a key mediator in the development of Type I hypersensitivity reactions, as its interaction with allergens like Der f 1 and Der f 2 triggers B-cell activation, proliferation, and subsequent class-switch recombination to IgE. These allergen-specific IgE antibodies then sensitize mast cells and basophils, leading to the release of inflammatory mediators upon re-exposure, which causes symptoms of allergic asthma, rhinitis, and atopic dermatitis. Therapeutic targeting of this BCR is primarily achieved through allergen-specific immunotherapy (AIT), which uses controlled doses of Dermatophagoides farinae extracts to induce immune tolerance and shift the B-cell response toward protective IgG4 antibodies. Emerging therapies also include monoclonal antibodies like quilizumab, which targets the M1 prime epitope of membrane IgE to deplete IgE-switched B cells, and experimental chimeric molecules designed to cross-link the BCR with inhibitory receptors to suppress pathogenic B-cell activity. By focusing on the specific B cells responsible for the allergic cascade, these approaches aim to provide long-term disease modification rather than just symptomatic relief.

Other names

House dust mite allergen-specific B-cell receptorDer f-specific B-cell receptorAnti-Der f B-cell receptorDermatophagoides farinae-specific BCRAllergen-specific B-lymphocyte receptor

Allergen-specific immunotherapy (AIT) induces immune tolerance by shifting the B-cell response from IgE to IgG4 production and inducing T-cell anergy. Monoclonal antibodies like quilizumab target the M1 prime epitope of membrane IgE on the B-cell receptor to deplete IgE-switched B cells. Experimental chimeric molecules cross-link the BCR with inhibitory receptors (e.g., FcγRIIb or CR1) to suppress B-cell activation or induce apoptosis.